SEARCH

SEARCH BY CITATION

References

  • Apidianakis Y & Rahme LG (2011) Drosophila melanogaster as a model for human intestinal infection and pathology. Dis Model Mech 4: 2130.
  • Ewbank JJ & Zugasti O (2011) C. elegans: model host and tool for antimicrobial drug discovery. Dis Model Mech 4: 300304.
  • Fernandes P (2006) Antibacterial discovery and development–the failure of success? Nat Biotechnol 24: 14971503.
  • Fujiyuki T, Imamura K, Hamamoto H & Sekimizu K (2010) Evaluation of therapeutic effects and pharmacokinetics of antibacterial chromogenic agents in a silkworm model of Staphylococcus aureus infection. Drug Discov Ther 4: 349354.
  • Gill JJ, Sabour PM, Leslie KE & Griffiths MW (2006) Bovine whey proteins inhibit the interaction of Staphylococcus aureus and bacteriophage K. J Appl Microbiol 101: 377386.
  • Gu J, Xu W, Lei L et al. (2011) LysGH15, a novel bacteriophage lysin, protects a murine bacteremia model efficiently against lethal methicillin-resistant Staphylococcus aureus infection. J Clin Microbiol 49: 111117.
  • Hamamoto H, Kurokawa K, Kaito C, Kamura K, Manitra Razanajatovo I, Kusuhara H, Santa T & Sekimizu K (2004) Quantitative evaluation of the therapeutic effects of antibiotics using silkworms infected with human pathogenic microorganisms. Antimicrob Agents Chemother 48: 774779.
  • Hamamoto H, Tonoike A, Narushima K, Horie R & Sekimizu K (2009) Silkworm as a model animal to evaluate drug candidate toxicity and metabolism. Comp Biochem Physiol C Toxicol Pharmacol 149: 334339.
  • Heo YJ, Lee YR, Jung HH, Lee J, Ko G & Cho YH (2009) Antibacterial efficacy of phages against Pseudomonas aeruginosa infections in mice and Drosophila melanogaster. Antimicrob Agents Chemother 53: 24692474.
  • Kaito C & Sekimizu K (2007) A silkworm model of pathogenic bacterial infection. Drug Discov Ther 1: 8993.
  • Kaito C, Akimitsu N, Watanabe H & Sekimizu K (2002) Silkworm larvae as an animal model of bacterial infection pathogenic to humans. Microb Pathog 32: 183190.
  • Klumpp J, Lavigne R, Loessner MJ & Ackermann HW (2010) The SPO1-related bacteriophages. Arch Virol 155: 15471561.
  • Kurokawa K, Kaito C & Sekimizu K (2007) Two-component signaling in the virulence of Staphylococcus aureus: a silkworm larvae-pathogenic agent infection model of virulence. Methods Enzymol 422: 233244.
  • Kutateladze M & Adamia R (2010) Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol 28: 591595.
  • Lavigne R & Ceyssens PJ (2012) Family Myoviridae. Virus Taxonomy: Ninth Report of the International Committee on Taxonomy of Viruses (King AM, Lefkowitz E, Adams MJ & Carstens EB, eds), pp. 4662. Elsevier Academic Press, San Diego, CA.
  • Lavigne R & Kropinski AM (2012) Family Podoviridae. Virus Taxonomy: Ninth Report of the International Committee on Taxonomy of Viruses (King AM, Lefkowitz E, Adams MJ & Carstens EB, eds), pp. 6385. Elsevier Academic Press, San Diego, CA.
  • Matsuzaki S, Yasuda M, Nishikawa H et al. (2003) Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage φMR11. J Infect Dis 187: 613624.
  • Powers JH (2004) Antimicrobial drug development–the past, the present, and the future. Clin Microbiol Infect 10(suppl 4): 2331.
  • Pukatzki S, Kessin RH & Mekalanos JJ (2002) The human pathogen Pseudomonas aeruginosa utilizes conserved virulence pathways to infect the social amoeba Dictyostelium discoideum. P Natl Acad Sci USA 99: 31593164.
  • Rashel M, Uchiyama J, Ujihara T et al. (2007) Efficient elimination of multidrug-resistant Staphylococcus aureus by cloned lysin derived from bacteriophage MR11. J Infect Dis 196: 12371247.
  • Ryan EM, Gorman SP, Donnelly RF & Gilmore BF (2011) Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy. J Pharm Pharmacol 63: 12531264.
  • Seed KD & Dennis JJ (2008) Development of Galleria mellonella as an alternative infection model for the Burkholderia cepacia complex. Infect Immun 76: 12671275.
  • Seed KD & Dennis JJ (2009) Experimental bacteriophage therapy increases survival of Galleria mellonella larvae infected with clinically relevant strains of the Burkholderia cepacia complex. Antimicrob Agents Chemother 53: 22052208.
  • Shields P & Tsang AY (2006) Mannitol Salt Agar Plates Protocols. Protocols. American Society for Microbiology, Washington, DC. www.microbelibrary.org Accessed 10 September 2012.
  • Synnott AJ, Kuang Y, Kurimoto M, Yamamichi K, Iwano H & Tanji Y (2009) Isolation from sewage influent and characterization of novel Staphylococcus aureus bacteriophages with wide host ranges and potent lytic capabilities. Appl Environ Microbiol 75: 44834490.
  • Talbot GH, Bradley J, Edwards JE, Gilbert D, Scheld M & Bartlett JG (2006) Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 42: 657668.
  • Uchiyama J, Rashel M, Takemura I, Wakiguchi H & Matsuzaki S (2008) In silico and in vivo evaluation of bacteriophage φEF24C, a candidate for treatment of Enterococcus faecalis infections. Appl Environ Microbiol 74: 41494163.
  • Uchiyama J, Takemura I, Satoh M, Kato S, Ujihara T, Akechi K, Matsuzaki S & Daibata M (2011) Improved adsorption of an Enterococcus faecalis bacteriophage φEF24C with a spontaneous point mutation. PLoS ONE 6: e26648.